The University of Southampton
University of Southampton Institutional Repository

Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases

Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases
Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases
A retrospective review of 115 consecutive patients (118 eyes) based at Southampton Eye Unit, treated with intravitreal bevacizumab for CNV was performed. Lesions of all types irrespective of size or location that were either ineligible for photodynamic therapy (PDT) under the National Health Service (including minimally classic and occult CNV) or those not responding to PDT (classic or predominantly classic CNV with recurrent or persistent CNV activity) were included in the study (table 1). All patients underwent visual acuity testing (best corrected Snellen), slitlamp examination and fundus fluorescein angiography. Central macular thickness (CMT) was assessed using Stratus optical coherence tomography (Carl Zeiss Meditec, USA). After discussion about the off-label nature of treatment and the potential risks, informed consent was obtained from all patients. Intravitreal bevacizumab 1.25 mg was injected via the pars plana under sterile conditions; topical antibiotics were given for five days postoperatively. Patients were followed up at 2–4 weeks and then at 1-month intervals; Repeat injections were offered in the event of persistent lesion activity (indicated by persistent intraretinal/subretinal fluid or fibrovascular pigment epithelial detachment). All patients were monitored for any systemic and ocular adverse events. Blood pressure was measured before and 4–6 weeks after treatment.
Snellen visual acuity was converted to a standard logarithm of the minimum angle of resolution scale and ETDRS letter score for statistical analysis.6 The Mann–Whitney test was used to compare the mean visual acuity and CMT, before and after treatment.
treatment, macular degeneration, eye
0007-1161
1716-1717
Madhusudhana, K.C.
38366182-3e2e-43fe-9fdd-d437bf7907d7
Hannan, S.R.
59e67ba3-13ba-4ae6-a1d3-80b1f8c0292f
Williams, C.P.R.
3e526564-a86c-4707-9168-a786e9aef448
Goverdhan, S.V.
9ae32d5a-5c82-48a4-962d-1ed8acc3991e
Rennie, C.
35078ab5-7248-40b2-8a50-b90d6d1394bc
Lotery, A.J.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Luff, A.J.
91a9d311-a6c6-4cf8-8aa2-d4129c6a3cdb
Newsom, R.S.B.
61a941d6-44a3-4c05-aff5-7f5450c5b75b
Madhusudhana, K.C.
38366182-3e2e-43fe-9fdd-d437bf7907d7
Hannan, S.R.
59e67ba3-13ba-4ae6-a1d3-80b1f8c0292f
Williams, C.P.R.
3e526564-a86c-4707-9168-a786e9aef448
Goverdhan, S.V.
9ae32d5a-5c82-48a4-962d-1ed8acc3991e
Rennie, C.
35078ab5-7248-40b2-8a50-b90d6d1394bc
Lotery, A.J.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Luff, A.J.
91a9d311-a6c6-4cf8-8aa2-d4129c6a3cdb
Newsom, R.S.B.
61a941d6-44a3-4c05-aff5-7f5450c5b75b

Madhusudhana, K.C., Hannan, S.R., Williams, C.P.R., Goverdhan, S.V., Rennie, C., Lotery, A.J., Luff, A.J. and Newsom, R.S.B. (2007) Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. British Journal of Ophthalmology, 91 (12), 1716-1717. (doi:10.1136/bjo.2006.108639).

Record type: Article

Abstract

A retrospective review of 115 consecutive patients (118 eyes) based at Southampton Eye Unit, treated with intravitreal bevacizumab for CNV was performed. Lesions of all types irrespective of size or location that were either ineligible for photodynamic therapy (PDT) under the National Health Service (including minimally classic and occult CNV) or those not responding to PDT (classic or predominantly classic CNV with recurrent or persistent CNV activity) were included in the study (table 1). All patients underwent visual acuity testing (best corrected Snellen), slitlamp examination and fundus fluorescein angiography. Central macular thickness (CMT) was assessed using Stratus optical coherence tomography (Carl Zeiss Meditec, USA). After discussion about the off-label nature of treatment and the potential risks, informed consent was obtained from all patients. Intravitreal bevacizumab 1.25 mg was injected via the pars plana under sterile conditions; topical antibiotics were given for five days postoperatively. Patients were followed up at 2–4 weeks and then at 1-month intervals; Repeat injections were offered in the event of persistent lesion activity (indicated by persistent intraretinal/subretinal fluid or fibrovascular pigment epithelial detachment). All patients were monitored for any systemic and ocular adverse events. Blood pressure was measured before and 4–6 weeks after treatment.
Snellen visual acuity was converted to a standard logarithm of the minimum angle of resolution scale and ETDRS letter score for statistical analysis.6 The Mann–Whitney test was used to compare the mean visual acuity and CMT, before and after treatment.

Full text not available from this repository.

More information

Published date: 2007
Keywords: treatment, macular degeneration, eye
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 62490
URI: http://eprints.soton.ac.uk/id/eprint/62490
ISSN: 0007-1161
PURE UUID: 68f8e03e-f775-4542-9d63-d61af1f66bd1
ORCID for A.J. Lotery: ORCID iD orcid.org/0000-0001-5541-4305

Catalogue record

Date deposited: 12 Sep 2008
Last modified: 17 Dec 2019 01:49

Export record

Altmetrics

Contributors

Author: K.C. Madhusudhana
Author: S.R. Hannan
Author: C.P.R. Williams
Author: S.V. Goverdhan
Author: C. Rennie
Author: A.J. Lotery ORCID iD
Author: A.J. Luff
Author: R.S.B. Newsom

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×